https://crisprmedicinenews.com/clinical-trial/hemophilia-b-mucopolysaccharidosis-mps-nct04628871/
Clinical trial: Hemophilia B & Mucopolysaccharidosis, MPS, (NCT04628871) - CRISPR Medicine
Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their...
clinical trialhemophilia bmucopolysaccharidosismpscrispr
https://www.symptoma.co.za/en/info/hemophilia-b
Hemophilia B (Christmas Disease): Symptoms, Diagnosis and Treatment - Symptoma South Africa
Hemophilia B, also known as Christmas disease, is an inherited, X-linked, recessive disorder, caused by a mutation in the gene encoding for coagulation factor...
diagnosis and treatmenthemophilia bdisease symptomschristmas
https://www.biopharmadive.com/news/pfizer-hemophilia-b-gene-therapy-fda-review/653990/
Pfizer’s hemophilia B gene therapy inches closer to regulatory approval | BioPharma Dive
The treatment could become Pfizer’s first marketed gene therapy, an area the pharma has poured significant resources into in recent years.
hemophilia bgene therapy
https://wv.bleeding.org/get-involved/event-calendar.html/event/2026/05/27/living-with-hemophilia-b-virtual-education-program/562243
Living with Hemophilia B: Virtual Education Program : Event Calendar : Get Involved : National...
living with hemophiliavirtual education
https://www.grandelakes.com/events/orlando/coalition-for-hemophilia-b-symposium-9808268
Coalition for Hemophilia B Symposium
Coalition for Hemophilia B Symposium
hemophilia bcoalitionsymposium
https://www.pak4ininhibitor.com/2024/03/22/hemophilia-b-with-fewer-populations-the-administrative-sector-should-secure-the/
Hemophilia B with fewer populations. The administrative sector should secure the |...
Mar 22, 2024 - Hemophilia B with fewer populations. The administrative sector should safe the provision of coagulation factor concentrates and eliminate all barriers to drug...
hemophilia bfewerpopulationsadministrativesector
https://www.hpnonline.com/surgical-critical-care/article/21288178/gene-therapy-for-treatment-of-adults-with-hemophilia-b-receives-fda-approval
Gene therapy for treatment of adults with Hemophilia B receives FDA approval | HPN Online
The U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of...